Efficacy and safety of 30% supramolecular salicylic acid in the treatment of rosacea

Efficacy and safety of 30% supramolecular salicylic acid in the treatment of rosacea: A Prospective Randomized Control Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029833

Enrollment

Unknown

Registered

2020-02-15

Start date

2017-10-01

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rosacea

Interventions

Experimental group:30% supramolecular salicylic acid combined with 0.75% Metronidazole Gel

control goup:0.75% Metronidazole Gel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Aged >=18 years, papulopustular rosacea

Exclusion criteria

Exclusion criteria: Patients with photosensitive diseases; any previous treatment with laser,light-based devices or chemical peel for rosacea during the prior 1 months; taking photo-sensitizing pharmaceuticals, topical treatments with corticosteroids, metronidazole or calcineurin inhibitors during the prior 3 months, pregnancy or breast feeding women, patients with other skin diseases such as seborrheic dermatitis, eczema and other serious systemic diseases.

Design outcomes

Primary

Measure	Time frame
erythema index;value of skin hydration;transdermal water loss(TEWL);score of non-transient erythema;score of lesions;score of transient erythema;score of burning;score of dryness;	—

Countries

China

Contacts

Public ContactXu Linghui

The Second Affiliated Hospital of Fujian Medical University

mimicooo@aliyun.com+86 13559365566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026